A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study
Sign Up to like & getrecommendations! Published in 2023 at "Life"
DOI: 10.3390/life13010191
Abstract: A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of… read more here.
Keywords: egfr protein; new anticancer; protein; semisynthetic theobromine ... See more keywords